These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 30091043)

  • 1. Process intensification of EB66® cell cultivations leads to high-yield yellow fever and Zika virus production.
    Nikolay A; Léon A; Schwamborn K; Genzel Y; Reichl U
    Appl Microbiol Biotechnol; 2018 Oct; 102(20):8725-8737. PubMed ID: 30091043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propagation of Brazilian Zika virus strains in static and suspension cultures using Vero and BHK cells.
    Nikolay A; Castilho LR; Reichl U; Genzel Y
    Vaccine; 2018 May; 36(22):3140-3145. PubMed ID: 28343780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perfusion Control for High Cell Density Cultivation and Viral Vaccine Production.
    Nikolay A; Bissinger T; Gränicher G; Wu Y; Genzel Y; Reichl U
    Methods Mol Biol; 2020; 2095():141-168. PubMed ID: 31858467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccine.
    Giel-Moloney M; Goncalvez AP; Catalan J; Lecouturier V; Girerd-Chambaz Y; Diaz F; Maldonado-Arocho F; Gomila RC; Bernard MC; Oomen R; Delagrave S; Burdin N; Kleanthous H; Jackson N; Heinrichs J; Pugachev KV
    Sci Rep; 2018 Sep; 8(1):13206. PubMed ID: 30181550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice.
    Kum DB; Boudewijns R; Ma J; Mishra N; Schols D; Neyts J; Dallmeier K
    Emerg Microbes Infect; 2020; 9(1):520-533. PubMed ID: 32116148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza A virus production in a single-use orbital shaken bioreactor with ATF or TFF perfusion systems.
    Coronel J; Behrendt I; Bürgin T; Anderlei T; Sandig V; Reichl U; Genzel Y
    Vaccine; 2019 Nov; 37(47):7011-7018. PubMed ID: 31266669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production.
    Tapia F; Vázquez-Ramírez D; Genzel Y; Reichl U
    Appl Microbiol Biotechnol; 2016 Mar; 100(5):2121-32. PubMed ID: 26758296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza viruses production: Evaluation of a novel avian cell line DuckCelt®-T17.
    Petiot E; Proust A; Traversier A; Durous L; Dappozze F; Gras M; Guillard C; Balloul JM; Rosa-Calatrava M
    Vaccine; 2018 May; 36(22):3101-3111. PubMed ID: 28571695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells.
    Genzel Y; Vogel T; Buck J; Behrendt I; Ramirez DV; Schiedner G; Jordan I; Reichl U
    Vaccine; 2014 May; 32(24):2770-81. PubMed ID: 24583003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purification of flavivirus VLPs by a two-step chomatographic process.
    Lima TM; Souza MO; Castilho LR
    Vaccine; 2019 Nov; 37(47):7061-7069. PubMed ID: 31201056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-cell-density cultivations to increase MVA virus production.
    Vázquez-Ramírez D; Genzel Y; Jordan I; Sandig V; Reichl U
    Vaccine; 2018 May; 36(22):3124-3133. PubMed ID: 29433897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and protective efficacy of an EB66
    Yang Z; Wang J; Wang X; Duan H; He P; Yang G; Liu L; Cheng H; Wang X; Pan J; Zhao J; Yu H; Yang B; Liu Y; Lin J
    Avian Pathol; 2020 Oct; 49(5):448-456. PubMed ID: 32374185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing Vero viable cell densities for yellow fever virus production in stirred-tank bioreactors using serum-free medium.
    Mattos DA; Silva MV; Gaspar LP; Castilho LR
    Vaccine; 2015 Aug; 33(35):4288-91. PubMed ID: 25930117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High cell density perfusion process for high yield of influenza A virus production using MDCK suspension cells.
    Wu Y; Bissinger T; Genzel Y; Liu X; Reichl U; Tan WS
    Appl Microbiol Biotechnol; 2021 Feb; 105(4):1421-1434. PubMed ID: 33515287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EB66® cell line as a valuable cell substrate for MVA-based vaccines production.
    Léon A; David AL; Madeline B; Guianvarc'h L; Dureau E; Champion-Arnaud P; Hebben M; Huss T; Chatrenet B; Schwamborn K
    Vaccine; 2016 Nov; 34(48):5878-5885. PubMed ID: 27997338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zika virus-like particles (VLPs): Stable cell lines and continuous perfusion processes as a new potential vaccine manufacturing platform.
    Alvim RGF; Itabaiana I; Castilho LR
    Vaccine; 2019 Nov; 37(47):6970-6977. PubMed ID: 31164305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus.
    Garg H; Mehmetoglu-Gurbuz T; Joshi A
    Sci Rep; 2020 Mar; 10(1):4017. PubMed ID: 32132648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of yellow fever virus in microcarrier-based Vero cell cultures.
    Souza MC; Freire MS; Schulze EA; Gaspar LP; Castilho LR
    Vaccine; 2009 Oct; 27(46):6420-3. PubMed ID: 19559120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of an acoustic settler versus a hollow fiber-based ATF technology for influenza virus production in perfusion.
    Gränicher G; Coronel J; Trampler F; Jordan I; Genzel Y; Reichl U
    Appl Microbiol Biotechnol; 2020 Jun; 104(11):4877-4888. PubMed ID: 32291490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures.
    Pereira RC; Silva AN; Souza MC; Silva MV; Neves PP; Silva AA; Matos DD; Herrera MA; Yamamura AM; Freire MS; Gaspar LP; Caride E
    Vaccine; 2015 Aug; 33(35):4261-8. PubMed ID: 25862300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.